Insider · CIK 0001182473
Terry J Rosen
Files at IDYA (IDEAYA Biosciences, Inc.), RCUS (Arcus Biosciences, Inc.). First filing Feb 27, 2025, latest Dec 18, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RCUS: Arcus Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Arcus Biosciences, Inc. | $1.2M 54,691 shares | -2% | +223% from low-15% from high | |
| 47Moderate | Arcus Biosciences, Inc. | $201k 19,800 shares | +1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -28,947 | $21.88 | $633k | 2,220,553 | Dec 18, 2025 |
| Dec 17, 2025 | RCUS Arcus Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -25,744 | $22.16 | $570k | 2,194,809 | Dec 18, 2025 |
| Jun 24, 2025 | IDYA IDEAYA Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 26, 2025 |
| Feb 27, 2025 | RCUS Arcus Biosciences, Inc. | POpen-market purchase Common Stock | +19,800 | $10.18 | $201k | 2,554,160 | Feb 27, 2025 |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Common Stock | +165,000 | $0.00 | $0 | 2,534,360 | Jan 27, 2025 |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Jan 27, 2025 |
| Dec 15, 2024 | RCUS Arcus Biosciences, Inc. | FTax withholding Common Stock | -37,882 | $16.08 | $609k | 2,369,360 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.